** Shares of Noxopharm rise as much as 33.3% to A$0.140, their highest since Nov. 16, 2023
** Stock posts its biggest intraday gain since Aug. 14
** Biotechnology co says preclinical testing for its brain cancer drug candidates shows significantly reduced tumour growth
** About 2.8 mln shares change hands, compared with the 30-day average volume of around 314,000
** Stock up 83.1% YTD, including session's move
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.